Executive management team members increase their holdings in Medivir

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that departing CEO, Niklas Prager, CEO designate Christine Lind and CFO Ola Burmark today have bought a total of 16.500 shares in Medivir. The purchase was made simultaneously with their sale of a total of 52.101 redemption rights, which were received in connection with the ongoing voluntary redemption program.

For more information, please visit the insider trading register at www.finansinspektionen.se

For further information, please contact:
Ola Burmark, CFO Medivir AB, mobile: +46 (0) 725 480 580

About Medivir
Medivir is a research based pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Medivir’s class B share is listed on the Nasdaq Stockholm Mid Cap List.


About Us

Medivir develops innovative pharmaceuticals for the treatment of cancer. The company specializes within protease inhibitor research and nucleotide/nucleoside science.The research is conducted in all phases of pharmaceutical development, from idea to clinical phase III studies. The development work is conducted both in-house and through partnerships.Medivir is listed on the Nasdaq Stockholm Mid Cap List.


Documents & Links